← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › VITAMINS › VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO › Vitamin D and analogues
dihydrotachysterol
A11CC02
Forms & Strengths
- Oral tablets: 0.125 mg
- Oral solution: 0.2 mL/mg
Adult Dosing
- Hypoparathyroidism: Initial 0.75 mg to 2.5 mg daily for several days, then maintenance 0.2 mg to 1 mg daily as required for normal serum calcium levels
- Hypocalcemia associated with hypoparathyroidism: Adjust dose based on serum calcium monitoring (target 9-10 mg/dL)
Pediatric Dosing
- Hypoparathyroidism (Neonates/Infants): Initial 0.05 mg to 0.1 mg daily, adjusted based on serum calcium
- Hypoparathyroidism (Children): Initial 0.1 mg to 0.5 mg daily, maintenance adjusted to clinical and laboratory response
Indications
- Hypoparathyroidism (sporadic, surgical, or idiopathic)
- Pseudohypoparathyroidism
- Postoperative hypocalcemia
Mechanism of Action
- Synthetic analog of vitamin D that functions similarly to calcitriol
- Promotes absorption of calcium and phosphate in the small intestine
- Enhances bone mineralization and renal tubular reabsorption of calcium
- Restores normal serum calcium levels in patients with deficient endogenous parathyroid hormone
Contraindications
- Hypercalcemia
- Malabsorption syndrome
- Hypervitaminosis D
- Hypersensitivity to dihydrotachysterol or any component of the formulation
Adverse Reactions
- Hypercalcemia (anorexia, nausea, vomiting, constipation, weakness)
- Hypercalciuria and nephrocalcinosis
- Polyuria, polydipsia, and nocturia
- Bone pain, headache, and soft tissue calcification
Drug Interactions
- Thiazide diuretics: Increased risk of hypercalcemia due to decreased renal calcium excretion
- Digitalis glycosides: Hypercalcemia potentiates cardiac arrhythmias
- Magnesium-containing antacids: Risk of hypermagnesemia, especially in chronic renal failure
- Mineral oil, cholestyramine, colestipol: Decreased intestinal absorption of dihydrotachysterol
Curated Content: Needs Vetting Before Put to Clinical Use